sanofi

Results Q4/FY 2025

January 29, 2026

Forward-looking statements

This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. With respect to any sustainability or environmental, social and governance (ESG)-related information contained herein, in light of the significant uncertainties inherent in such statements and other related information contained herein, investors should not regard these statements as a representation or warranty by Sanofi or any other person that Sanofi will achieve its goals, objectives, aspirations, metrics, plans or targets, which may be subject to evaluation and adjustment, in any specified time frame or at all, the achievement of which shall remain subject to other conditions and considerations both within and outside Sanofi's control. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Brand names appearing in this presentation are trademarks of Sanofi and/or its affiliates. Not all trademarks related to products under development have been approved as of the date of this presentation by the relevant health authorities.

Abbreviations used in the main presentation are defined in the list of abbreviations. In the appendices, abbreviations are written in full the first time used.

Agenda

01 **Business**
Paul Hudson

02 **Finance**
François Roger

03 **Pipeline**
Houman Ashrafian

04 **Q&A**
Presenters and Olivier Charmeil, Brian Foard, Brendan O'Callaghan, Roy Papatheodorou, and Thomas Triomphe



2025: strong commercial and financial *delivery*

Active portfolio management and capital allocation

- Opella proceeds reinvested in BD/M&A
- €5bn share buyback completed
- Growing dividend for 31 years

Compelling growth

9.9% *growth* in sales

One new blockbuster (ALTUVIIIO)

€5.7bn *sales* of newly launched medicines and vaccines

Diversified pipeline to benefit patients

Internal pipeline

Three new launches: Qfitlia (haemophilia), Wayrilz (ITP), Nuvaxovid (COVID-19)

Positive data for *key pipeline*: amlitelimab (AD), brivekimig (HS), duvakitug (IBD), efdoralprin alfa (AATD), vaccines (flu, rabies, RSV)

New *phase 3* programs: Wayrilz, lunsekimig, duvakitug, yellow fever

Strategic and innovative *phase 1* programs, including *three new* gene therapies

Augmented by select acquisitions

dren bio

vigil NEURO

blueprint MEDICINES

vicebio

DYNAVAX [1]

All percentage changes at CER. 1. The acquisition of Dynavax is currently pending; it is expected to close in Q1 2026 subject to the satisfaction of customary closing conditions.

Q4: *continued* sales growth



- **Pharma launches**
  Driven by Ayvakit and ALTUVIIIO
- **Vaccines**
  Beyfortus performance offset by phasing; flu driven by strong in-season epidemiology
- **Other medicines**
  Sales growth impacted by divestments
- **Dupixent**
  >€4bn in the quarter for a second time

All percentage changes at CER. 1. ALTUVIIIO, Nexviazyme, Sarclisa, Ayvakit, Rezurock, Cablivi, Xenpozyme, Tzield, Qfitlia, and Wayrilz.

Launches: *34%* growth in 2025

Sales (€m)		*Q4*	*FY*
Beyfortus		686	1,781
ALTUVIIIO		324	1,160
Nexviazyme		203	790
SARCLISA		157	588
AYVAKIT	NEW	168	305[1]
REZUROCK		113	490
Cablivi		69	271
Xenpozyme		61	228
Tzield		16	63
NUVAXOVID™	NEW	9	29
Qfitlia	NEW	4	9
WAYRILZ	NEW	6	7
		1,816	*5,721*
		+17.1%	*+34.0%*

All percentage changes at CER. 1. On a pro-forma basis, Ayvakit full-year sales were $725m.

Dupixent: strong volume growth; sales reached *€15.7bn* in 2025



Q4: growth reflected continued penetration across established indications and new launches (**COPD, CSU, BP**), as well a US gross-to-net true-up in Q4 2024

FY: >30% patient growth

#1 biologic prescribed by dermatologists, pulmonologists, allergists, and ENTs[1]

Continuously expanding benefit

- **asthma children:** JP approval (Dec)
- **AFRS:** US regulatory acceptance (Nov), potential 9th indication
- **CSU:** EU approval (Nov)

All percentage changes at CER. 1. IQVIA SMART Patient insights edition H2 2025 weekly average NBRx through December 19, 2025.

Vaccines: sustained *leadership* in Influenza and RSV



Influenza

Q4: higher vaccination rate due to prolonged influenza season

FY: market share gain of Fluzone High-Dose/Flublok despite soft vaccination rate in US; higher vaccination rate in EU

Beyfortus

Q4: different phasing between Q4 and Q3 versus last year
FY: immunisation programs now in >45 countries

Polio/Pertussis/Hib and Meningitis, travel and endemic

Steady performance reflecting underlying market trends, including lower global birth cohort

All percentage changes at CER.

Vaccines: augmenting pipeline and *protecting older adults*

vicebio

- Bivalent RSV+HMPV vaccine with strong immune responses in phase 1 study for both RSV and HMPV; targeting thermostable ready-to-use liquid formulation
- Molecular Clamp technology for vaccine antigen design
- Acquisition closed in December 2025

DYNAVAX

- HEPLISAV-B, the leading US adult hepatitis B vaccine with a differentiated two-dose regimen[1]
- Shingles vaccine candidate currently in phase 1/2 studies
- Closing expected in Q1 2026

1. Competitor's hepatitis B vaccines are given in three doses over six months.

Sanofi leads industry working group on *PAS 2090*, a defining moment for *sustainable healthcare*

Key lifecycle stages



Examples: eco-design for footprint reduction

Dupixent

Optimise API manufacturing

Toujeo and Hexaxim

Enhance manufacturing, packaging, devices production

1st global standard[1] to measure and communicate the environmental impact of medicines and vaccines across their lifecycle

1. Standard sponsored by NHS England, the Office for Life Sciences, and the Pharmaceutical life-cycle assessement Consortium (11 pharma companies led by Sanofi and sponsored by the SMI Health TaskForce and the Pharmaceutical Environmental Group).

sanofi

Finance

Q4/FY 2025

Q4: *strong* quarter

(€m)	*Q4 2024*	*Q4 2025*	*Change*
Net sales	**10,564**	**11,303**	**+13.3%**
Business gross profit	**7,844**	**8,518**	**+15.6%**
Business gross margin	74.3%[1]	75.4%[1]	+1.1pp
R&D	-2,257	-2,291	+6.6%
SG&A	-2,648	-2,746	+9.6%
Operating expenses	**-4,905**	**-5,037**	**+8.2%**
Percentage of net sales	46.4%	44.6%	-1.8pp
Other operating income and expenses	-886	-1,178	+43.0%
Business operating income	**2,078**	**2,341**	**+21.7%**
Business operating margin	19.7%[1]	20.7%[1]	+1.0pp
Effective tax rate	18.8%	18.5%	-0.3pp
Total business net income	**1,642**	**1,856**	**+22.3%**
Average number of shares, million	1,253.6	1,212.7	-3.3%
Business EPS	**1.31**	**1.53**	**+26.7%**

Sales

Double-digit growth led by Dupixent and pharma launches

Business gross margin

+1.1pp, driven by product mix and efficiencies

Operating expenses

R&D: moderate increase
SG&A: driving growth and preparing for launches

Business operating income

Strong increase supported by operating expense leverage, partly offset by profit sharing

Business EPS

+26.7%, reflecting operating income growth

All percentage changes at CER. 1. Margin at actual exchange rates.

Sales growth driven by *strong volume developments*



+34%

compounded volume growth over the last three years

1. Excludes hyperinflation impact and Opella for comparison purposes.

Delivering *profitable growth* while investing in 2025

Sales growth

+9.9%

Growth led by Dupixent and pharma launches

2025 guidance high single-digit percentage[1]

Business gross margin[2]

+1.8pp

Driven by product mix and efficiencies

Operating expenses[2]

+€448m
R&D

Increase driven by BD/M&A

+€360m
SG&A

Driving growth and preparing for launches

Business EPS growth

+15.0%

Reflecting operating income growth and share buyback (+12.2% excluding SBB)

2025 guidance low double-digit percentage[3]

All percentage changes at CER. Barring unforeseen events. 1. Excludes any impact from hyperinflation. 2. At actual exchange rates. 3. Before share buyback.

Solid free cash flow generation

(€bn)



Free cash flow definition is in appendix 9 of the Q4 and FY 2025 results press release.

1. Others includes €733m of factoring, -€162m of capex net of depreciations, €15m of interests paid, €191m of tax paid, €148m of restructuring, -€386m of forex impact and -€397m of other items excluding tax.

Strong balance sheet, with an intention to retain AA rating

(€bn)



See appendix 5 of the Q4 and FY 2025 results press release for more details. Credit ratings reaffirmed: Moody's Aa3/stable, S&P AA/stable, Scope AA/stable as of December 31, 2025. 1. Before restructuring, acquisitions and disposals.

Capital allocation policy *executed* in 2025

Organic investments[1]

R&D	*+€448m*
Sales & marketing	*+€360m*

Business development/M&A

€10.4bn Opella proceeds reinvested into:

Blueprint	*€8.4bn*
Dynavax	*€1.9bn*
Vicebio	*€1.0bn*
Dren Bio DR-0201	*€0.5bn*
Vigil Neuroscience	*€0.4bn*

Increased dividend for the 31st consecutive year

Proposed dividend[2]

€4.12

(+5.1%)

Share buyback

Program completed

€5bn

1. At actual exchange rates. 2. Subject to approval at the annual general meeting on April 29, 2026.

2026 *business dynamics* to consider

P&L

Sales

- Divestments of other medicines: c.€200m (sales impact)
- Vaccines: slightly negative growth

Business gross margin

Increase

Operating expense control

- R&D: moderate increase (before BD/M&A)
- Sales and marketing: increase to support growth/launches
- G&A: stable

Other operating income/expenses

- Capital gains (divestments): c.€500m
- Profit sharing increasing faster than sales growth
- REGN development balance[1]: decrease by c.€400m over 2025
- Amvuttra royalty[1]: increase by c.€500m[2] over 2025

Financial income/expenses

Expected increase due to 2025 and 2026 BD/M&A

Effective tax rate

Stable

Guidance (at CER)

Sales growth
Business EPS growth

high single-digit percentage[3]
slightly faster than sales[4]

Share buyback
€1bn

All percentage changes at CER. Barring unforeseen events. For full-year 2026, and based on January 2026 average currency exchange rates, a currency impact of approximately -2% on sales and -3% on business EPS is anticipated.
1. For additional details, please refer to the appendix slide 35. 2. Based on Sanofi estimates for 2026 and 2027 using EUR/USD rate at 1.15. 3. Excludes any impact from hyperinflation. 4. Before share buyback.

sanofi

Pipeline

2025: *sustainable* progress across the pipeline

Pipeline delivery
Mid to late stage

12 phase 3 readouts

15 phase 2 readouts

10 new molecules entered clinical development, including

3 gene therapies

Regulatory scorecard
More options to more patients

Three launches
Medicines and vaccines

Qfitlia

First RNAi antithrombin in **hemophilia A** and **B** approved in the US and China

WAYRILZ™

First BTK inhibitor in **ITP** approved in the US and the EU, under review in Japan

Nuvaxovid™ (COVID-19 Vaccine, Adjuvanted)

First recombinant **COVID-19 vaccine** with full approval in the US and the EU

As of December 16, 2025. 1. Includes the US, EU, Japan, and China.

Pipeline: Q4 *highlights*

Regulatory approvals	**Dupixent**	CSU (EU), asthma children (JP)
	Teizeild	T1D, stage 2 (EU)
	Wayrilz	ITP (EU)
	Cerezyme	GD3 (US)
	Cablivi	aTPP (CN), children (US)
	Qfitlia	haemophilia (CN)
	Myqorzo	hypertrophic cardiomyopathy (CN)
	Redemplo	familial chylomicronemia syndrome (CN)
Regulatory submission acceptances	**Dupixent**	AFRS (US priority review), CSU children (JP)
	Tzield	T1D, stage 2 children (US priority review)
	SP0087	rabies (EU)
Phase 3 starts	**duvakitug**	CD (STARSCAPE-1/2), UC (SUNSCAPE-1/2)
	Wayrilz	IgG4-related diseases (RILIEF)

Phase 3 readouts

amlitelimab	AD program positive results
Dupixent	AFRS primary endpoint met
tolebrutinib	PPMS primary endpoint not met



tolebrutinib (BTK inhibitor)

PPMS: phase 3 did not meet the primary endpoint; no regulatory submission

SPMS: US complete response

For abbreviations, please see slide 48.

amlitelimab: new data provide increasing confidence in long-term *sustained* and progressive benefit and patient convenience

Progressively increasing efficacy

Endpoints/percent of patients

		COAST 1 Week 24		COAST 2 Week 24		SHORE Week 24		ATLANTIS	
		Q4W	Q12W	Q4W	Q12W	Q4W	Q12W	Week 24	Week 52
Non-responder imputation	vIG1-AD	21.1%	22.5%	25.3%	25.7%	28.7%	32.3%	35.4%	50.3%
	EASI-75	35.9%	39.1%	41.8%	40.5%	48.1%	46.8%	62.9%	76.5%
Treatment policy	vIG1-AD	26.5%	29.1%	28.8%	27.7%	29.9%	32.9%		
	EASI-75	46.0%	50.3%	49.7%	45.9%	50.9%	48.1%		

Key observations

Data in three phase 3 studies; one phase 2

- Potential for **quarterly** dosing from the start
- Efficacy **progressively** increasing throughout the treatment period
- **No evidence of plateau** through Week 24 and 52
- Monotherapy or in combination with topical corticosteroids

- Well-tolerated, **acceptable** safety profile

Further phase 3 data and global regulatory submission in **H2 2026**

Source: amlitelimab COAST 1: https://www.sanofi.com/assets/dotcom/pressreleases/2025/2025-09-04-05-00-00-3144170-fr.pdf. COAST 2, SHORE, and ATLANTIS: https://www.sanofi.com/assets/dotcom/pressreleases/2026/2026-01-23-06-00-00-3224400-en.pdf.

amlitelimab: majority of OCEANA AD program now *delivered*

Phase 2		*Phase 3*	
SC efficacy and safety ✓	STREAM-AD	coast 1 ✓ / coast 2 ✓	
effect on vaccine antibody response	hydro	shore ✓	with background TCS/TCI
long-term safety, tolerability, and efficacy	atlantis / river-AD	estuary	blinded maintenance response and safety
		aqua	with background TCS/TCI and inadequate response to biologics/JAK inhibitors



Readout from AQUA and ESTUARY phase 3 studies in **H2 2026**

China: significant progress with regional strategy

Approvals
Global medicines

Cablivi caplacizumab-yhdp
vWF-A1 Nanobody®
VHH for the treatment of
acquired thrombotic thrombocytopenic purpura

Qfitlia (fitusiran)
Small antithrombin interfering RNA in
haemophilia A and B

China-only medicines

MYQORZO (aficamten)
Small molecule cardiac myosin inhibitor for the treatment of
obstructive hypertrophic cardiomyopathy

Redemplo (plozasiran) injection
Small APOC3 RNAi reducing triglycerides in patients with
familial chylomicronaemia symptoms

Pipeline: key *mid- and late-stage* development projects

Immunology

amlitelimab	phase 3 AD potential LCM ✓
lunsekimig	phase 2 asthma potential LCM
brivekimig	phase 2a HS potential LCM ✓
duvakitug	phase 2 IBD started phase 3 CD/UC ✓
balinatunfib	phase 2 potential combo ✓
itepekimab	phase 3 COPD* ✓ ✗
SAR449028 (BLU-808)	phase 2 CIndU, CSU
SAR444336 (non-beta IL2)	phase 2 MC
SAR445399 (IL1R3 mAb)	phase 2 HS

Rare diseases/Oncology

Wayrilz	approved ITP (US, EU) potential LCM ✓
elenestinib	phase 3 SM
venglustat	phase 3 GD3, Fabry disease
efdoralprin alfa	phase 2 AATD ✓
Sarclisa	approved 1L, R/R MM submitted SC ✓

Neurology

tolebrutinib	under review SPMS (EU)
frexalimab	phase 3 RMS, SPMS
riliprubart	phase 3 CIDP potential LCM

Vaccines

Fluzone HD	phase 3 flu 50 years+ ✓
SP0087	phase 3 rabies ✓
SP0202	phase 3 pneumococcal disease children
SP0218	phase 3 yellow fever
SP0230	phase 2 meningitis
SP0256	phase 2 RSV+HMPV older adults ✓
SP0289/SP0335	phase 2 flu H5 pandemic

wholly owned | with partner

As of December 31, 2025. *Itepekimab met the primary endpoint in one of two COPD phase 3 studies. Itepekimab's future development in COPD is dependent on further analysis of phase 3 data and regulatory feedback. A check mark indicates the availability of the first data for/achievement of the clinical development milestone mentioned in the box; green colour indicates primary endpoint(s) met; red cross indicates phase 3 primary endpoint not met.

Pipeline: *upcoming* news flow

H1 2026	H2 2026	2027
Nexviazyme – IOPD	amlitelimab – AD (remaining data)	frexalimab – RMS
lunsekimig – asthma	venglustat – Fabry disease	Dupixent – LSC	brivekimig – HS	riliprubart – CIDP
SP0230 – meningitis	venglustat – GD3		itepekimab – CRSwNP	SP0202 – PCV
			fitusiran – hemophilia A/B	SP0218 – yellow fever
venglustat – Fabry disease (US)	Dupixent – CSU children (US, EU)	Dupixent – LSC (US)	Dupixent – CSU children (JP)	fitusiran – hemophilia A/B (EU, JP)	riliprubart – CIDP (US, EU)
venglustat – GD3	Tzield – T1D, S3 (US)	amlitelimab – AD	Wayrilz – ITP (JP)	frexalimab – RMS (US, EU)	SP0218 – yellow fever (US, EU)
Fluzone HD – flu 50y+ (US, EU)	Tzield – T1D, S2 children (US)	Nexviazyme – IOPD (US)	SP0087 – rabies (EU)		
Dupixent – AFRS (US)	tolebrutinib – SPMS (EU)	efdoralprin alfa – AATD (US)			
Dupixent – BP (EU, JP)	Sarclisa – SC (US, EU, JP)	SP0087 – rabies (US)			

As of December 31, 2025. Key pipeline news flow only.

regulatory decision | regulatory submission | phase 3 data readout | phase 2 data readout

Q&A session

To ask a question

By Zoom 

Click on the
Raise hand icon

Check your audio device
is well connected

By phone 

Raise and lower
your hand: dial *9

Unmute and mute
your microphone: dial *6

Any problems? 

Email us:
investor.relations@sanofi.com

sanofi

Appendix Finance

Q4 sales

	Q4 2025 (€m)	*Change*
Dupixent	4,246	32.2%
Beyfortus	686	-14.9%
Influenza, COVID-19	575	31.5%
Polio/Pertussis/Hib primary vaccines and Boosters	551	-9.5%
Lantus	419	1.1%
Toujeo	332	18.6%
ALTUVIIIO	324	53.0%
Fabrazyme	252	-1.1%
Meningitis, Travel and endemic vaccines	227	-4.8%
Plavix	214	7.6%
Nexviazyme/Nexviadyme	203	15.8%
Lovenox	179	-21.6%
Cerezyme	171	2.9%
Ayvakit	168	-
Sarclisa	157	27.7%
Alprolix	149	-4.1%
Industrial Sales	136	13.7%
Praluent	132	20.0%
Kevzara	131	10.3%
Thymoglobulin	124	6.4%

All percentage changes at CER.

FY sales

	FY 2025 (€m)	*Change*
Dupixent	15,714	25.2%
Polio/Pertussis/Hib primary vaccines and Boosters	2,554	-4.4%
Influenza, COVID-19	2,314	-5.8%
Beyfortus	1,781	9.5%
Lantus	1,733	10.3%
Toujeo	1,345	12.0%
Meningitis, Travel and endemic vaccines	1,287	0.8%
ALTUVIIIO	1,160	77.6%
Fabrazyme	1,019	0.1%
Plavix	910	3.1%
Lovenox	822	-14.4%
Nexviazyme/Nexviadyme	790	21.4%
Cerezyme	695	-3.9%
Alprolix	603	7.0%
Sarclisa	588	28.5%
Praluent	526	9.3%
Myozyme	519	-21.0%
Kevzara	507	23.6%
Rezurock	490	8.7%
Thymoglobulin	490	3.7%

All percentage changes at CER.

FY: delivering *profitable growth*

(€m)	FY 2024	FY 2025	Change
Net sales	**41,081**	**43,626**	**+9.9%**
Business gross profit	**31,091**	**33,793**	**+12.7%**
Business gross margin	75.7%[1]	77.5%[1]	+1.8pp
R&D	-7,394	-7,842	+8.8%
SG&A	-9,183	-9,543	+7.3%
Operating expenses	**-16,577**	**-17,385**	**+7.9%**
Percentage of net sales	40.4%	39.9%	-0.5pp
Other operating income and expenses	-3,293	-4,424	+40.2%
Business operating income	**11,343**	**12,149**	**+11.9%**
Business operating margin	27.6%[1]	27.8%[1]	+0.2pp
Effective tax rate	19.8%	19.9%	+0.1pp
Total business net income	**8,912**	**9,555**	**+12.1%**
Average number of shares, million	1,251.4	1,220.4	-2.5%
Business EPS	**7.12**	**7.83**	**+15.0%**

Sales
Growth led by Dupixent and launches

Business gross margin
+1.8pp, driven by product mix and efficiencies

Operating expenses
R&D: increase driven by BD/M&A
SG&A: driving growth and preparing for launches

Business operating income
Strong increase supported by operating expense leverage, partly offset by profit sharing

Business EPS
+15.0%, reflecting operating income growth and share buyback

All percentage changes at CER. 1. Margin at actual exchange rates.

Currency impact

Sales (€m)



Business EPS (€)



Currency sensitivity and exposure

2026 business EPS currency sensitivity

Currency	Variation	Net sales sensitivity	Business EPS sensitivity
US Dollar	+0.05 USD/EUR	-€1,069m	-€0.23
Japanese Yen	+5 JPY/EUR	-€46m	-€0.02
Chinese Yuan	+0.2 CNY/EUR	-€60m	-€0.02
Brazilian Real	+0.4 BRL/EUR	-€44m	-€0.01

Currency average rates

	Q4 2024	Q4 2025	Change
€/US Dollar	1.067	1.164	+9.1%
€/Yen	162.434	179.327	+10.4%
€/Yuan	7.685	8.253	+7.4%
€/Real	6.229	6.273	+0.7%
€/Ruble	106.724	92.886	-13.0%

Currency exposure on Q4 2025 sales



Considerations for other operating income and expenses

Reimbursement of development balance by Regeneron

- Sanofi funds majority of development costs[1]
- Regeneron reimburses up to 50% of cumulative costs[2]

Regeneron development balance reimbursement
(€bn)



Amvuttra® royalty[5]

- Recently approved in the US and EU for ATTR-CM
- Royalty on global net sales in all indications (30% on sales above $1.5bn)[6]

Amvuttra® royalty[7]
(€bn)



1. Sanofi funds 100% upfront until first positive phase 3, then 80% thereafter. 2. Via a quarterly payment of 20% of Regeneron's profit share. 3. As of December 31, 2025, the "Development balance" amounted to €0.5bn at closing rate.
4. Development balance expected to be fully reimbursed around mid-year 2026. 5. Alnylam medicine. 6. Royalty details: 15% from $0-$150m; 17.5% from $150m-$300m; 20% from $300m-$500m; 25% from $500m-$1.5bn; and 30% above $1.5bn.
7. Actuals for 2023, 2024 and 2025 at annual actual exchange rate and Sanofi estimates for 2026 and 2027 using EUR/USD rate at 1.15.

sanofi

Appendix Pipeline



Pipeline: *registration* and *phase 3*

Registration

Dupixent[A]	IL4R mAb	allergic fungal rhinosinusitis (US)
		bullous pemphigoid (EU, JP)
Tzield	CD3 mAb	type 1 diabetes, stage 3 (US)
Wayrilz	BTK inhibitor	immune thrombocytopenia (JP)
tolebrutinib	BTK inhibitor	secondary progressive multiple sclerosis (US, EU)
Sarclisa	CD38 mAb subcutaneous	relapsed/refractory multiple myeloma

Phase 3

Immunology

amlitelimab	OX40L mAb	atopic dermatitis
Dupixent	IL4R mAb	chronic pruritus of unknown origin
		lichen simplex chronicus
duvakitug	TL1A mAb	Crohn's disease
		ulcerative colitis
itepekimab	IL33 mAb	chronic obstructive pulmonary disease*
		chronic rhinosinusitis with nasal polyps
lunsekimig	IL13xTSLP Nanobody® VHH	chronic obstructive pulmonary disease
Rezurock	ROCK2 inhibitor	chronic lung allograft dysfunction

Rare diseases

Nexviazyme	enzyme replacement therapy	infantile-onset Pompe disease
elenestinib	D816V-mutated KIT inhibitor	indolent/smoldering systemic mastocytosis
fitusiran	RNAi targeting antithrombin	hemophilia A and B (EU, JP)
Wayrilz	BTK inhibitor	Sickle cell disease
		IgG4-related disease
		warm autoimmune hemolytic anemia
venglustat	oral GCS inhibitor	Fabry disease
		Gaucher disease type 3

Neurology

frexalimab[1]	CD40L mAb	relapsing multiple sclerosis
		non-relapsing secondary progressive multiple sclerosis
riliprubart[2]	C1s mAb	SOC-refractory chronic inflammatory demyelinating polyneuropathy
		IVIg-treated chronic inflammatory demyelinating polyneuropathy

Oncology

Sarclisa	CD38 mAb	newly diagnosed multiple myeloma, transplant eligible (HD7) (US)
		newly diagnosed multiple myeloma, transplant eligible (IsKia)
		smoldering multiple myeloma (ITHACA)

Vaccines

Fluzone HD[4]	multivalent inactivated	flu (50+ years)
SP0087	vero cell	rabies
SP0202	21-valent conjugate	pneumococcal disease (children)
SP0218	vero cell	yellow fever

As of December 31, 2025. For collaborations, please see slide 47. For abbreviations, please see slide 48. Pediatric and adolescents' indication extensions are not included.
*Itepekimab's future development in COPD is dependent on further analysis of phase 3 data and regulatory feedback. 1. Also known as SAR441344. 2. Also known as SAR445088. 3. Also known as SP0178.

Pipeline: *phase 2*

Immunology

amlitelimab	OX40L mAb	asthma
balinatunfib[1]	oral TNFR1 signaling inhibitor	Crohn's disease
		ulcerative colitis
brivekimig	TNFaxOX40L Nanobody® VHH	Crohn's disease
		hidradenitis suppurativa
		type 1 diabetes, stage 3
		ulcerative colitis
frexalimab[2]	CD40L mAb	type 1 diabetes
itepekimab	IL33 mAb	chronic rhinosinusitis without nasal polyps
lunsekimig[3]	IL13xTSLP Nanobody® VHH	asthma
		asthma, high-risk
		atopic dermatitis
		chronic rhinosinusitis with nasal polyps
riliprubart[4]	C1s mAb	antibody-mediated rejection
rilzabrutinib	BTK inhibitor	asthma
		chronic spontaneous urticaria
SAR449028[5]	wild-type KIT inhibitor	chronic induced/spontaneous urticaria
		allergic rhinoconjunctivitis
SAR444336	non-beta IL2 Synthorin™	microscopic colitis
SAR445399[6]	IL1R3 mAb	hidradenitis suppurativa

Rare diseases

Wayrilz	BTK inhibitor	Graves' disease
efdoralprin alfa[7]	AAT fusion protein	alpha-1 antitrypsin deficiency emphysema
frexalimab **rilzabrutinib** **brivekimig**	CD40L mAb BTK inhibitor TNFaxOX40L Nanobody® VHH	focal segmental glomerulosclerosis/ minimal change disease

Oncology

SAR445877[8]	PD1xIL15 fusion protein	solid tumors
Sarclisa	CD38 mAb	relapsed/refractory multiple myeloma in combination

Neurology

SAR402663	sFLT01 AAV gene therapy	wet age-related macular degeneration

Vaccines

SP0230	5-valent ACWY+B	meningitis
SP0256	mRNA	respiratory syncytial virus+human metapneumovirus (older adults)
SP0268	mRNA	acne
SP0289	mRNA	flu H5 pandemic
SP0335	inactivated adjuvanted	flu H5 pandemic

As of December 31, 2025. For collaborations, please see slide 47. For abbreviations, please see slide 48. Paediatric and adolescents' indication extensions are not included.
1. Also known as SAR441566. 2. Also known as SAR441344. 3. Also known as SAR443765. 4. Also known as SAR445088. 5. Also known as BLU-808. 6. Also known as MAB212, in-licensed from MAB Discovery.
7. Also known as SAR447537 and formerly known as INBRX-101. 8. Also known as KD050.

Pipeline: *phase 1*

Immunology

SAR446422	CD28xOX40 bispecific Ab	inflammatory indication
SAR446959	MMP13xADAMTS5xCAP Nanobody® VHH	knee osteoarthritis
SAR448501[1]	CD20 bispecific mAb	inflammatory indication

Neurology

SAR446597	BbxC1s AAV gene therapy	geographic atrophy in dry age-related macular degeneration
SAR448851[2]	TREM2 agonist	Alzheimer's disease

Rare diseases

SAR446268	DMPK AAV gene therapy	myotonic dystrophy type 1

Oncology

SAR445953	CEACAM5-Topo1 ADC	colorectal cancer
SAR446523	GPRC5D mAb	relapsed/refractory multiple myeloma

Vaccines

SP0287	Fluzone HD+Nuvaxovid	flu+COVID-19
SP0287	Flublok+Nuvaxovid	flu+COVID-19
SP0291	mRNA	respiratory syncytial virus+human metapneumovirus+parainfluenza type 3 (older adults)
SP0269	mRNA	chlamydia
SP0340[3]	subunit	respiratory syncytial virus+human metapneumovirus (older adults)
SP0341[4]	subunit	respiratory syncytial virus+human metapneumovirus+parainfluenza type 3 (older adults)

As of December 31, 2025. For collaborations, please see slide 47. For abbreviations, please see slide 48. Pediatric and adolescents' indication extensions are not included.
1. Also known as DR-0201. 2. Formerly known as VG-3927. 3. Also known as VXB-251. 4. Also known as VXB-351.

Pipeline: *Q4 appendix changes*

New in

Registration

Dupixent – allergic fungal rhinosinusitis (US)

Phase 3

duvakitug – Crohn's disease

duvakitug – ulcerative colitis

Wayrilz – IgG4-related disease

Phase 2

SAR444336 – microscopic colitis

SAR445399 – hidradenitis suppurativa

Phase 1

SAR446597 – geographic atrophy in dry age-related macular degeneration

SAR446268 – myotonic dystrophy type 1

SP0340 – respiratory syncytial virus+human metapneumovirus older adults

SP0341 – respiratory syncytial virus+human metapneumovirus+parainfluenza type 3 older adults

Designations

US priority review **Dupixent** – allergic fungal rhinosinusitis

US priority review **Tzield** – type 1 diabetes, stage 2 children

EU orphan **efdoralprin alfa** – alpha-1 antitrypsin deficiency emphysema

CN priority review **Cablivi** – acquired thrombotic thrombocytopenic purpura

Removed from

Registration

Dupixent – chronic spontaneous urticaria (EU) (approved)

Teizeild – type 1 diabetes, stage 2 (EU) (approved)

Qfitlia – hemophilia A and B (CN) (approved)

Wayrilz – immune thrombocytopenia (EU) (approved)

Cerezyme – Gaucher disease type 3 (US) (approved)

aficamten – hypertrophic cardiomyopathy (CN) (approved)

plozasiran – familial chylomicronemia syndrome (CN) (approved)

Phase 3

Dupixent – allergic fungal rhinosinusitis (to registration)

tolebrutinib – primary progressive multiple sclerosis (negative)

Phase 2

amlitelimab – alopecia areata (deprioritised)

amlitelimab – celiac disease (deprioritised)

amlitelimab – systemic sclerosis (deprioritised)

balinatunfib – rheumatoid arthritis (completed)

Dupixent – ulcerative colitis (deprioritised)

duvakitug – Crohn's disease/ulsecrative colitis (to phase 3)

eclitasertib – ulcerative colitis (deprioritised)

frexalimab – systemic lupus erythematosus (deprioritised)

itepekimab – bronchiectasis (deprioritised)

Wayrilz – IgG4-related disease (to phase 3)

SAR447873 – gastroenteropancreatic neuroendocrine tumors (deprioritised)

Phase 1

SAR444335 – microscopic colitis (to phase 2)

SAR445399 – hidradenitis suppurativa (to phase 2)

SAR445514 – inflammatory indication (deprioritised)

SAR446159 – Parkinson's disease (deprioritised)

SP0237 – flu (deprioritised)

As of December 31, 2025. For collaborations, please see slide 47. For abbreviations, please see slide 48.

Pipeline: *partnerships* with rights to license

Partner	*Target*	*Indication*
Nurix	STAT6 degrader	inflammatory indication
Recludix	SAR448755, STAT6 inhibitor	inflammatory indication
Recursion	orally active small molecules	inflammatory indication, oncology
Earendil Labs (Helixon)	TL1Axa4b7 mAb TL1AxIL23p19 mAb additional targets	inflammatory indication
C4X	oral IL17A inhibitor	inflammatory indication
Kymera	IRAK4 degrader	inflammatory indication
Scribe Tx	RNA-guided CRISPR-associated programs	rare disease
Adel	SAR449548/ADEL-Y01, acK280 tau mAb	Alzheimer's disease
Innate Pharma	anti-B7H3 NK cell engager	oncology
SK bioscience	next-generation conjugate vaccines (children, adults)	pneumococcal disease



As of December 31, 2025. For abbreviations, please see slide 48.

Pipeline: *regulatory designations* since 2020

Orphan

- **Dupixent** – AFRS (US)
- **ALTUVIIIO** – hemophilia A (US, EU)
- **Qfitlia** – hemophilia A/B (US, EU)
- **Wayrilz** – IgG4-RD (US, EU), ITP (US, EU, JP), SCD (US), wAIHA (US)
- **Rezurock** – cGvHD (US)
- **Cerdelga** – Gaucher (US)
- **Nexviazyme** – Pompe (US, JP)
- **Xenpozyme** – ASMD (US, EU, JP)
- **venglustat** – Fabry, Gaucher (US, EU, JP)
- **efdoralprin alfa** – AATD (US, EU)
- **SAR446268** – DM1 (US, EU)
- **riliprubart** – AMR (US), CIDP (US, EU, JP)
- **Sarclisa** – MM (US)
- **SAR446523** – R/R MM (US)

Fast track (US)

- **itepekimab** – COPD
- **ALTUVIIIO** – hemophilia A
- **Qfitlia** – hemophilia A/B
- **Wayrilz** – IgG4-RD, ITP
- **Nexviazyme** – Pompe
- **Xenpozyme** – ASMD
- **venglustat** – Fabry
- **efdoralprin** – AATD
- **SAR446268** – DM1
- **SAR446597** – GA
- **SAR402663** – wet AMD
- **CD123 NKCE** – AML
- **Beyfortus** – RSV
- **SP0125** – RSV (toddlers)
- **SP0202** – pneumococcal disease
- **SP0087** – rabies
- **Fluzone HD+Nuvaxovid** – flu+COVID-19
- **Flublok+Nuvaxovid** – flu+COVID-19
- **SP0289** – flu (H5 pandemic)
- **SP0256** – RSV+HMPV (older adults)
- **SP0269** – chlamydia

Breakthrough therapy

- **Dupixent** – AD (US)
- **Dupixent** – COPD (US)
- **Dupixent** – EoE (US)
- **Rezurock** – cGvHD (US)
- **ALTUVIIIO** – hemophilia A (US, CN)
- **Qfitlia** – hemophilia A/B (US)
- **Nexviazyme** – Pompe (US)
- **Xenpozyme** – ASMD (US)
- **Ayvakit** – advSM (US)
- **tolebrutinib** – SPMS (US)
- **riliprubart** – CIDP (CN)
- **Beyfortus** – RSV (US, CN)

PRIME (EU)

- **Xenpozyme** – ASMD
- **Beyfortus** – RSV
- **SP0125** – RSV (toddlers)

SAKIGAKE (JP)

- **Xenpozyme** – ASMD

Priority review

- **Dupixent** – AD children (US), AFRS (US), BP (US, CN), COPD (US), CRSwNP adolescents (US), EoE (US) children (US), PN (US, CN)
- **Kevzara** – RA (US)
- **Tzield** – T1D, stage 2 (CN), children (US)
- **Tzield** – T1D, stage 3 (US[1])
- **Soliqua** – T2D (CN)
- **Rezurock** – cGvHD (US)
- **ALTUVIIIO** – hemophilia A (US)
- **Nexviazyme** – Pompe (US, JP, CN)
- **Cablivi** – aTTP (children US, JP, CN)
- **Xenpozyme** – ASMD (US)
- **Ayvakit** – GIST (US), advSM (US), ISM (US)
- **tolebrutinib** – SPMS (US)
- **Sarclisa** – NDMM, 1L TI (US)
- **Fexinidazole** – HAT (US)
- **Beyfortus** – RSV (CN)

Accelerated assessment

- **Dupixent** – PN (CN)
- **Xenpozyme** – ASMD (EU)
- **Beyfortus** – RSV (EU)

As of December 31, 2025. For abbreviations, please see slide 48. 1. In addition to the CNPV granted by the FDA.

What's next: Immunology



As of December 31, 2025. Pediatric and adolescents' indication extensions are not included. Dashed lines represent future clinical study starts, barring unforeseen events. For abbreviations, please see slide 48. Illustrative; selected projects only.
1. itepekimab's future development in COPD is dependent on further analysis of phase 3 data and regulatory feedback.

What's next: Vaccines



As of December 31, 2025. Illustrative; selected projects only. For abbreviations, please see slide 48.

Pipeline: main clinical studies across *disease areas*

Immunology

amlitelimab (OX40L mAb)
- AD (COAST 1: NCT06130566, COAST 2: NCT06181435, SHORE: NCT06224348, AQUA: NCT06241118, ESTUARY: NCT06407934)
- asthma (TIDE-Asthma: NCT05421598)

balinatunfib (oral TNFR1si)
- CD (SPECIFIC-CD: NCT06637631)
- UC (SPECIFIC-UC: NCT06867094)

brivekimig (TNFaxOX40L Nanobody® VHH)
- CD (CHROMA CD: NCT06958536)
- HS (BRIGHTEN: NCT07170917)
- T1D, stage 3 (NCT06812988)
- UC (COLOR UC: NCT06975722)

Dupixent (IL4R mAb)
- AFRS (LIBERTY-AFRS-AI: NCT04684524)
- BP (NCT04206553)
- CPUO (NCT05263206)
- CSU (Study B: NCT04180488)
- lichen simplex chronicus (STYLE 1: NCT06687967, STYLE 2: NCT06687980)

duvakitug (TL1A mAb)
- Crohn's disease (STARSCAPE-1: NCT07184931, STARSCAPE-2: NCT07184944)
- ulcerative colitis (SUNSCAPE-1: NCT07184996, SUNSCAPE-2: NCT07185009)

frexalimab (CD40L mAb)
- T1D, stage 3 (FABULINUS: NCT06111586)

itepekimab (IL33 mAb)
- COPD (AERIFY-1:NCT04701983, AERIFY-2: NCT04751487, AERIFY-3: NCT0532641, AERIFY-4: NCT06208306)
- CRSwNP (CEREN 1: NCT06834347, CEREN 2: NCT06834360)
- CRSsNP (NCT06691113)

lunsekimig (IL13xTSLP Nanobody® VHH)
- moderate to severe asthma (AIRCULES: NCT06102005)
- high-risk asthma (AIRLYMPUS: NCT06676319)
- AD (NCT06790121)
- COPD (PERSEPHONE: NCT07190209, THESEUS: NCT07190222)
- CRSwNP (NCT06454240)

Rezurock (ROCK2 inhibitor)
- chronic lung allograft dysfunction (ROCKaspire: NCT06082037)

riliprubart (C1s inhibitor)
- AMR (NCT05156710)

rilzabrutinib (BTK inhibitor)
- asthma (NCT05104892)
- CSU (RILECSU: NCT05107115)

teplizumab (CD3 mAb)
- T1D, stage 2 (delay onset of stage 3) (PETITE-T1D: NCT05757713)
- T1D, stage 3 (delay progression) (PROTECT Extension: NCT04598893)
- T1D, stage 3 (delay progression) (BETA PRESERVE: NCT07088068)

SAR449028 (wild-type KIT inhibitor)
- chronic induced/spontaneous urticaria (NCT06931405)
- allergic rhinoconjunctivitis (NCT06922448)

SAR444336 (non-beta IL2 Synthorin™)
- microscopic colitis (NCT07156175)

SAR445399 (IL1R3 mAb)
- HS (CLAROS: NCT07225569)

SAR446422 (CD28xOX40 bispecific Ab)
- inflammatory indication

SAR446959 (MMP13xADAMTS5xCAP Nanobody® VHH)
- knee osteoarthritis (NCT06704932)

SAR448501 (CD20 bispecific antibody)
- inflammatory indication (NCT06647069)

Rare diseases

Nexviazyme (enzyme replacement therapy)
- IOPD (Mini-COMET: NCT03019406 and Baby-COMET: NCT04910776)

efdoralprin alfa (AAT fusion therapy)
- AATD (NCT05856331, ELEVAATE OLE: NCT05897424)

elenestinib (oral KIT D816V inhibitor)
- indolent/smoldering systemic mastecytosis (HARBOR: NCT04910685)

fitusiran (RNAi targeting antithrombin)
- hemophilia A and B (ATLAS-OLE: NCT03754790, ATLAS-PEDS: NCT03974113, ATLAS-NEO: NCT05662319)

frexalimab/rilzabrutinib/brivekimig
- focal segmental glomerulosclerosis/minimal change disease (RESULT: NCT06500702)

venglustat (oral GCS inhibitor)
- Fabry disease (PERIDOT: NCT05206773, CARAT: NCT05280548)
- GD3 (LEAP2MONO: NCT05222906)

Wayrilz (BTK inhibitor)
- Graves' disease (NCT06984627)
- IgG4-RD (RILIEF: NCT07190196)
- ITP (LUNA 3: NCT04562766)
- Sickle cell disease (LIBRA: NCT06975865)
- wAIHA (LUMINA 3: NCT07086976)

SAR446268 (DMPK AAV gene therapy)
- DM1 (BrAAVe: NCT06844214)

As of December 31, 2025. For abbreviations, please see slide 48.

Pipeline: main clinical studies across *disease areas*

Neurology

frexalimab (CD40L mAb)
- RMS (FREXALT: NCT06141473)
- nrSPMS (FREVIVA: NCT06141486)
- MS (FREXCITE: NCT07325292)

riliprubart (C1s inhibitor)
- SOC-refractory CIDP (MOBILIZE: NCT06290128)
- IVIg-treated CIDP (VITALIZE: NCT06290141)
- long-term study (NCT06859099)

tolebrutinib (BTK inhibitor)
- SPMS (HERCULES: NCT04411641)
- PPMS (PERSEUS: NCT04458051)

SAR402663 (sFLT01 AAV gene therapy)
- wet AMD (NCT06660667)

SAR446597 (Factor Bb/C1s AAV gene therapy)
- dry AMD (NCT07215234)

SAR448851 (TREM2 agonist)
- Alzheimer's disease (NCT06343636)

Oncology

Sarclisa (CD38 mAb)
- MM, 1L TE (GMMG-HD7: NCT03617731)
- MM, 1L TE (IsKia: NCT04483739)
- smoldering MM (NCT04270409)
- R/R MM (IRAKLIA: NCT05405166)
- R/R MM (NCT04643002)

SAR445877 (PD1xIL15 fusion protein)
- solid tumors (NCT05584670)

SAR445953 (CEACAM5-Topop1 ADC)
- colorectal cancer (NCT06131840)

SAR446523 (GPRC5D mAb)
- R/R MM (NCT06630806)

Vaccines

Fluzone HD (inactivated quadrivalent)
- flu (50 years+) (NCT06641180)

SP0087 *(vero cell)*
- rabies (NCT04127786)

SP0202 *(*21-valent conjugate*)*
- pneumococcal disease (NCT06736041, NCT06975878)

SP0218 *(vero cell)*
- yellow fever (NCT07002060)

SP0230 *(*5-valent (ACWY+B)*)*
- meningitis (NCT06128733 and NCT06647407)

SP0256 *(mRNA)*
- RSV+HMPV (older adults) (NCT06134648, NCT06686654)

SP0268 *(mRNA)*
- acne (NCT06316297)

SP0289 *(mRNA)*
- flu (H5 pandemic) (NCT06727058)

SP0335 *(inactivated adjuvanted)*
- flu pandemic (NCT06560151)

SP0287 *(Fluzone HD+Nuvaxovid)*
- flu+COVID-19 (NCT06695117)

SP0287 *(Flublok+Nuvaxovid)*
- flu+COVID-19 (NCT06695130)

SP0291 *(mRNA)*
- RSV+hMPV+PIV3 (older adults) (NCT06604767)

SP0269 *(mRNA)*
- chlamydia (NCT06891417)

SP0340 *(subunit)*
- RSV+HMPV (older adults) (NCT06556147)

SP0341 *(subunit)*
- RSV+HMPV+PIV3 (older adults) (NCT07295028)

As of December 31, 2025. For abbreviations, please see slide 48.

Collaborations

Ref	Name	Companies
	aficamten	Cytokinetics
	ALTUVIIIO	Swedish Orphan Biovitrum (Sobi)
	Beyfortus	AstraZeneca
	Dupixent itepekimab Kevzara	Regeneron
	duvakitug	Teva Pharmaceuticals
	frexalimab	ImmuNext
	Nuvaxovid	Novavax
	plozasiran	Arrowhead
	SAR445953	Pfizer
	SAR447873	RadioMedix, Orano Med
	SAR449548	Adel
	SP0202	SK bioscience

Abbreviations

AAT	alpha-1-antitrypsine
AATD	alpha-1-antitrypsine deficiency
AAV	adeno-associated virus
Ab	antibody
AD	atopic dermatitis
ADC	antibody drug conjugate
AFRS	allergic fungal rhinosinusitis
AML	acute myeloid leukemia
AMR	antibody-mediated rejection
API	active pharmaceutical ingredient
APOC3	apolipoprotein C3
ASMD	acid sphingomyelinase deficiency
aTTP	acquired thrombotic thrombocytopenic purpura
ATTR-CM	transthyretin amyloid cardiomyopathy
BP	bullous pemphigoid
BTK	Bruton's tyrosine kinase
CD	cluster of differentiation
CD	Crohn's disease
CEACAM5	carcinoembryonic antigen cell adhesion molecule 5
cGvHD	chronic graft-versus-host disease
CIDP	chronic inflammatory demyelinating polyneuropathy
CIndU	cold induced urticaria
COPD	chronic obstructive pulmonary disease
CPUO	chronic pruritus of unknown origin
CRISPR	clustered regularly interspaced short palindromic repeats
CSU	chronic spontaneous urticaria
C1s	complement component 1s
d/wAMD	dry/wet age-related macular degeneration
DMPK	dystrophia myotonica protein kinase
DM1	myotonic dystrophy type 1
EASI-75	eczema area and severity index
ENT	ear, nose, and throat doctor
EoE	eosinophilic esophagitis
FeNO	fractional exhaled nitric oxide
GA	geographic atrophy
GCS	glucosylceramide synthase
GD1/3	Gaucher disease type 1 or 3
GIST	gastro-intestinal stromal tumor
GPRC5D	G-protein-coupled receptor class 5 member D
HAT	human african trypanosomiasis
HD	High-Dose
HMPV	human metapneumovirus
HS	hidradenitis suppurativa
IBD	inflammatory bowel disease
vIGA	validated investigator global assessment
IGF1R	insulin-like growth factor 1 receptor
IgG4-RD	IgG4-related disease
IL	interleukin
IOPD	infante-onset pompe disease
IRAK4	interleukin-1 receptor-associated kinase-4
ITP	immune thrombocytopenia
IV	intravenous
IVIg	intravenous immunoglobulin
LCM	lifecycle management
LD	loading dose
LSC	lichen simplex chronicus
mAb	monoclonal antibody
MC	microscopic colitis
MM	multiple myeloma
mRNA	messenger RNA
MTX	methotrexate
NBRx	new-to-brand prescription
NDMM	newly diagnosed multiple myeloma
NfL	neurofilament light chain
NK	natural killer
OBI	on-body injector
OX40L	OX40 ligand
PAS	publicly available specification
PCV	pneumococcal conjugate vaccine
pJIA	polyarticular juvenile idiopathic arthritis
PMR	polymyalgia rheumatica
PN	prurigo nodularis
PPMS	primary progressive multiple sclerosis
Q4/12W	every four/twelve weeks
RA	rheumatoid arthritis
RMS	relapsing multiple sclerosis
RNAi	RNA interference
ROCK2	rho associated coiled-coil containing protein kinase 2
RRD	response rate difference
R/R	relapsed/refractory
RSV	respiratory syncytial virus
SC	subcutaneous
SCD	Sickle cell disease
sJIA	systemic juvenile idiopathic arthritis
SLE	systematic lupus erythematosus
SM	systemic mastocytosis
SSTR	somatostatin receptor
SOC	standard of care
SPMS	secondary progressive multiple sclerosis
STAT6	signal transducer and activator of transcription 6
TCI	topical calcineurin inhibitor
TCS	topical corticosteroid
TE/I	transplant-eligible/ineligible
TL1A	TNF-like ligand 1a
TNF	tumor necrosis factor
TREM2	triggering receptor expressed on myeloid cells 2
TSLP	thymic stromal lymphopoietin
T1/2D	type 1/2 diabetes
UC	ulcerative colitis
vWF	von Willebrand factor
wAIHA	warm autoimmune hemolytic anemia


sanofi